City of Hope shared a post on LinkedIn:
“Today’s FDA approval of daraxonrasib marks an important new chapter for patients facing metastatic pancreatic cancer — one that will expand access to this new breakthrough treatment.
City of Hope is proud to have been among 59 centers worldwide that enrolled patients in the landmark clinical trial that helped bring this therapy forward, and among the first to help patients access it through the FDA-authorized Expanded Access Program.
City of Hope has long been a leader in translational pancreatic cancer research and care. In 2024, that work gained new momentum with a $150 million gift from philanthropists A. Emmet Stephenson Jr. and Tessa Stephenson Brand to help speed progress against one of the deadliest cancers. The gift launched a worldwide effort (Stephenson Global Pancreatic Cancer Research Institute) focused on advancing new ideas and bringing researchers together to move discoveries forward faster.
Pancreatic cancer remains one of the most difficult cancers to treat, making advances like this especially meaningful. Every breakthrough represents more time, more possibilities and more hope for patients and families facing this disease.”
Other posts about City of Hope on OncoDaily.